PT  - JOURNAL ARTICLE
AU  - Karamacoska, Diana
AU  - Chan, Daniel K.Y.
AU  - Leung, Isabella
AU  - Liu, Jian-xun
AU  - Brodaty, Henry
AU  - Fahey, Paul P
AU  - Bensoussan, Alan
AU  - Chang, Dennis H.
TI  - Study Protocol for a Phase III Randomised Controlled Trial of Sailuotong (SLT) for Vascular Dementia and Alzheimer’s Disease with Cerebrovascular Disease
AID  - 10.1101/2022.03.24.22271670
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.24.22271670
4099  - http://medrxiv.org/content/early/2022/03/27/2022.03.24.22271670.short
4100  - http://medrxiv.org/content/early/2022/03/27/2022.03.24.22271670.full
AB  - Background Vascular dementia (VaD) accounts for 15-20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng, Ginkgo biloba and Crocus sativus extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention.Methods A rigorous phase III clinical trial was developed with the aim of recruiting 238 patients diagnosed with mild to moderate probable VaD, or VaD mixed with Alzheimer’s disease (where cerebrovascular disease is the clinical dominant contributor to dementia, abbreviated as CVD+AD). Using a permuted block strategy, participants will be randomly allocated to receive SLT (120 mg bd) or placebo capsules for an intervention period of 52 weeks and will be followed-up for an additional 13 weeks. The primary outcome measures are the Vascular Dementia Assessment Scale-cognitive subscale and Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale. Secondary outcome measures include the Clinician’s Interview Based Impression of Change-Plus, CLOX, EXIT-25, Neuropsychiatric Inventory-Clinician rating scale, and Dementia Quality of Life questionnaire. Safety is assessed through adverse event reports and liver, renal, and coagulation studies.Discussion Primary and secondary outcome measures will be compared between treatment and placebo groups, using intention to treat and per protocol analyses. We hypothesise that a 52-week treatment of SLT will be clinically effective and well tolerated in participants with VaD or AD+CVD. This project will provide vital efficacy and safety data for this novel treatment approach to VaD.Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN 12616000057482. Registered on 20 January 2016. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369471&isReview=trueCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12616000057482Funding StatementAustralia Shineway Technology Pty Ltd provide the funding and medication to support the conduct of this trial. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of South West Sydney Local Health District and Western Sydney University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.VaDVascular dementiaADAlzheimer’s DiseaseCVDCerebrovascular DiseaseCVD+ADCerebrovascular Disease mixed with Alzheimer’s DiseaseSLTSailuotongNINDS-AIRENNational Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en NeurosciencesNINCDS-ADRDANational Institute of Neurological and Communication Disorders and Stroke-Alzheimer’s Disease and Related Disorders AssociationHRHeart RateBPBlood PressureHtHeightWtWeightMMSEMini Mental State ExamGDSGeriatric Depression ScaleVaDAS-cogVascular Dementia Assessment Scale-cognitive subscaleADCS-ADLAlzheimer’s Disease Cooperative Study-Activities of Daily LivingCIBIC-PlusClinician’s Interview Based Impression of Change-PlusNPI-CNeuropsychiatric Inventory-Clinician scaleDEMQOLDementia Quality of Life questionnaireCon medsConcomitant medicationsAEAdverse EventSAESerious Adverse EventULNUpper Limit of NormalTGATherapeutic Goods AdministrationPIPrincipal InvestigatorDSMBData and Safety Monitoring Board